

Author Year Setting N	Diagnosis; Previous AD courses	Pharmacogenomic test platform; treatment regimen, duration, follow-up	Patient demographics	Remission and response (Guided vs usual care)	Quality of life; Precision	Harms
Breitenstein 2014 <sup>15</sup> Hospital 116	MDD (HAM-D $\geq 14$ ); NR	ABCB1 genotyping; Duration of hospital stay (varied by patient, average NR), genotype results received at 4th week	44.8% male 47.6 years 100% white	Remission (HAM-D <10) at discharge: 83.6% vs 62.1% (P=0.005)	NR	NR
Hall-Flavin 2012 <sup>16</sup> Outpatient behavioral health clinic 44	MDD (HAM-D $\geq 14$ ); Average # previous antidepressant trials = 4.4	GeneSight; 8 wk follow-up	45% male 42.35 years 100% white	QIDS-C16: Overall reduction in depression scores: 31.2% vs 7.2% (P=.002) HAM-D: Overall reduction in depression scores: 30.8% vs 18.2% (P=.04)	NR	NR
Hall-Flavin 2013 <sup>17</sup> Hospital 227	MDD (HAM-D $\geq 14$ ), DDNOS; Average # previous panel medication trials =3.45	GeneSight; 8 wk follow-up	26.9% male 42.5 years 100% white	Significant response = 50% reduction in QIDS-C16 score: 44.4% vs 23.7% (OR=2.58; 95% CI 1.33 to 5.03; P=0.05)	NR	NR

MDD=Major Depressive Disorder; AD=Antidepressant; HAM-D=Hamilton Rating Scale for Depression; QIDS-C16: Quick Inventory of Depressive Symptomatology, Clinician Rated; DDNOS=Depressive Disorder Not Otherwise Specified; NR=Not reported; OR=Odds Ratio